1
|
Hurwitz JC, Santos V, Akerman M, Mendez C, Sanchez A, Corcoran A, Katz A, Lepor H, Taneja S, Carpenter TJ, Evans AJ, Mahadevan A, Haas JA, Lischalk JW. Multifocal MRI-Directed Simultaneous Integrated Boost (SIB) in the Treatment of Prostate Cancer with Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys 2023; 117:e395. [PMID: 37785324 DOI: 10.1016/j.ijrobp.2023.06.1521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Conventionally fractionated MRI-directed radiation boosts in the treatment of prostate cancer have been shown to improve oncologic outcomes in the FLAME trial. Moreover, recent data has demonstrated local recurrences following SBRT predominately occur at the site of the dominant intraprostatic lesion. Modern protocols including HYPO-Flame have demonstrated early safety profiles of a 5-fraction intraprostatic SBRT boost. This study aims to determine if multifocal SIB treatment is associated with additional acute toxicity relative to unifocal boosts. MATERIALS/METHODS In this single-center retrospective analysis, we identified all patients who underwent SBRT with a SIB using a robotic radiosurgical platform. Fiducial markers and hydrogel rectal spacers were placed prior to simulation. All patients underwent treatment planning MRI with documented PI-RADS 3-5 lesions targeted for SIB delineation. Patients were treated to a prescription dose of 3500 to 3625 cGy in 5 fractions, or 1800 to 2100 cGy in 3 fractions in concert with pelvic nodal irradiation. The SIB prescription dose ranged from 4000 to 4200 cGy and 2100 to 2300 cGy for the 5- and 3-fraction regimens, respectively. Acute toxicity was defined as that occurring within 60 days of treatment completion using the CTCAE v. 5.0. RESULTS A total of 35 patients with a median age of 70 underwent SBRT SIB from 5/2022 to 1/2023 with the following risk distribution: low (3%), intermediate (66%), high (28%), and regional (3%). Most patients received rectal spacers (77%) and neoadjuvant ADT (71%) prior to treatment. The majority of patients underwent 5-fraction SBRT (74%) with the remainder receiving SBRT as a boost. Approximately half (51%) of the cohort was treated with a multifocal SIB to multiple PI-RADS lesions. Mean SIB dose was 4105 and 2377 cGy in 5- and 3-fractions, respectively. With a median follow up of 33 days, we identified no grade 3+ acute toxicities. Crude rate of grade 2 GU and GI toxicity was 51% and 6%, respectively, on par with prior unifocal publications. There was no difference in median SIB volume between uni- and multifocal boosts (1.47 vs. 1.72 cc, p = 0.57), nor was SIB volume associated with an increased risk of grade 2 GU toxicity (p = 0.28). Dominant lesion location was not associated with increased grade 2 GU toxicity (p = 0.29). No grade 2 GI toxicities occurred in the multifocal group. Finally, univariate analysis did not identify multifocal boost as a risk of grade 2 GU toxicity (35%) relative to unifocal (67%) boost (p = 0.09). CONCLUSION In the first analysis of its kind in the literature, we demonstrate that multifocal MRI-directed intraprostatic SBRT SIB yields no acute high-grade toxicity and is not associated with a higher risk of low-grade GU and GI toxicity relative to unifocal boost. Longer follow is necessary to determine risk of late toxicity and oncologic efficacy.
Collapse
Affiliation(s)
- J C Hurwitz
- Department of Radiation Oncology, New York University Long Island School of Medicine, Mineola, NY
| | - V Santos
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - M Akerman
- Division of Health Services Research, New York University Long Island School of Medicine, Mineola, NY
| | - C Mendez
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - A Sanchez
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - A Corcoran
- Department of Urology, New York University Langone Hospital - Long Island, Mineola, NY
| | - A Katz
- Department of Urology, New York University Langone Hospital - Long Island, Mineola, NY
| | - H Lepor
- NYU Langone Medical Center, Manhattan, NY
| | - S Taneja
- Department of Urology, Perlmutter Cancer Center at New York University Grossman School of Medicine, New York, NY
| | - T J Carpenter
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - A J Evans
- Department of Radiation Oncology, NYU Langone Health and Perlmutter Cancer Center, New York, NY
| | | | - J A Haas
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - J W Lischalk
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| |
Collapse
|
2
|
DiBartolo D, Spuhler K, Clancy O, Haas J, Lischalk JW, Witten M, Carpenter TJ. Comparative Dosimetry for Hippocampal-Avoidant Whole Brain Radiotherapy with Helical Tomotherapy and VMAT Planning Techniques. Int J Radiat Oncol Biol Phys 2023; 117:e98-e99. [PMID: 37786228 DOI: 10.1016/j.ijrobp.2023.06.865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The advent of hippocampal-avoidant whole brain radiotherapy (HA-WBRT) has allowed for substantial improvements in cognition without compromising the efficacy of palliative whole brain radiotherapy. Volumetric modulated arc therapy (VMAT), a form of rotational intensity-modulated radiation therapy (IMRT), allows for rapid treatment delivery and minimizes fractional treatment time. However, given the intrinsic complexity of HA-WBRT planning, standard VMAT techniques require significant departmental resources and often fail to achieve planning objectives. We hypothesize that treatment planning and delivery on a helical tomotherapy (HT) unit improves OAR dosimetry compared to standard VMAT techniques. MATERIALS/METHODS Patients with multiple brain metastases who received WBRT with palliative intent were included in this single institution dosimetric study. Treatment objectives and dose constraints for HA-WBRT from NRG CC001 were utilized. Three separate plans were generated for each patient including Dual-Arc Conventional VMAT (DAC), Split-Arc Partial-Field VMAT (SAPF), and HT for dosimetric comparison. VMAT plans were generated using 6-MV photon beams with a maximum dose rate of 600 MU/min with a 120-leaf MLC. DAC plans utilized 2 coplanar arcs each with jaw tracking. SAPF plans used four partial arcs, and the field size of each beam was reduced to allow the MLC to block the centrally located hippocampus without sacrificing the whole brain PTV coverage. HT plans with a dose rate of 1000MU/min and Helical Delivery mode used a 2.5cm dynamic Jaw setting. Mean differences in target volume coverage and OAR dosimetry between planning approaches were calculated. Two-tailed, paired Student's t-tests were employed to determine statistically significant differences between DAC, SAPF, and HT plans. RESULTS A total of 15 treatment plans were generated for five patients (5 DAC, 5 SAPF, and 5 HT plans). HT was seen to significantly reduce hippocampal D100% compared to both DAC (∆-114.16 cGy, p = 0.001) and SAPF (∆-125.76 cGy, p < 0.001). Moreover, HT hippocampal D0.03cc was significantly lower than DAC (∆-80.26 cGy p = 0.003) and SAPF (∆-174.40 cGy, p < 0.001). At the same time, PTV coverage as determined by D98% was significantly higher compared to both DAC (∆ +372.66 cGy, p = <0.001) and SAPF (∆ +304 cGy, p = <0.001). CONCLUSION Compared to both DAC and SAPF, HT planning for HA-WBRT provides significant improvements in target coverage and OAR sparing. Additional research is warranted to determine whether further reductions in dose to the hippocampi provide additional clinical benefit.
Collapse
Affiliation(s)
- D DiBartolo
- Department of Medical Physics, Perlmutter Cancer Center, NYU Langone Long Island, Mineola, NY
| | - K Spuhler
- Department of Medical Physics, Perlmutter Cancer Center, NYU Langone Long Island, Mineola, NY
| | - O Clancy
- Department of Medical Physics, Perlmutter Cancer Center, NYU Langone Long Island, Mineola, NY
| | - J Haas
- Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Long Island, Mineola, NY; Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - J W Lischalk
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY; NYCyberKnife Perlmutter Cancer Center, NYU, New York, NY
| | - M Witten
- Department of Medical Physics, Perlmutter Cancer Center, NYU Langone Long Island, Mineola, NY
| | - T J Carpenter
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| |
Collapse
|
3
|
Mendez C, Lischalk JW, Katz A, Carpenter TJ, Witten MR, Sanchez A, Santos V, Corcoran A, Awad E, Trivedi I, Blacksburg SR, Haas J. Robotic SBRT in Prostate Cancer Patients Younger Than 50 Years Old-Updated Results. Int J Radiat Oncol Biol Phys 2023; 117:e417. [PMID: 37785375 DOI: 10.1016/j.ijrobp.2023.06.1568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic Body Radiation Therapy (SBRT) is a standard therapeutic option for men with prostate adenocarcinoma. The median age of prostate cancer in the US is 66 but patients as young as 35 have been reported. Many younger patients will have surgery rather than SBRT for localized prostate cancer but some will be treated with SBRT. There is a paucity of data on the outcomes of this younger subset. This study reports updated outcomes on patients younger than 50 treated with SBRT at a single institution and compares outcomes to older patients. MATERIALS/METHODS Between April 2006 and December 2022, 6,130 patients with prostate cancer were treated with inhomogeneous-dosed SBRT using a robotic linear accelerator. Information was available for 4,143 patients. 3568 (86.12%) of patients were treated with a median dose of 3500cGY (3500-3625) delivered over 5 consecutive fractions prescribed to the 83-85% isodose line, and the remaining 575 (13.88%) other patients receiving a median dose of 4500cGY (4500-5400) to the pelvis in conventional fractionation followed by a 3 fraction SBRT boost of 2100 cGY (1950-2100) over 3 consecutive fractions. Androgen deprivation Therapy (ADT) was prescribed in 1,035 (24.98%) of these cases. The mean age was 67.4 years old. 48 patients were younger than 50 years old (mean age 46.6). 4,095 patients were 50 or older. Patients were divided into prognostic D'Amico risk groups with 43.75%, 50.00%, 6.25% of patients falling in the low, intermediate, and high-risk stratifications in the younger cohort and 23.88%, 57.05%, 19.07% in the older cohort respectively. Pretreatment PSA was 1.72 - 43.2 (median: 5.4) in the younger group and 0.3 - 661 (median: 6.5) in the older group. In the younger group, Gleason scores were 6 in 47.92%, 7 in 47.92%, and 8-10 in 4.16%. 44 younger patients were treated with SBRT alone. 4 patients also received supplemental external beam radiation (median dose 4500cGY) and 5 patients (10.42%) received Androgen Deprivation Therapy (ADT) as part of their treatment regimen. In the older group, Gleason scores were 6 in 29.84%, 7 in 54.14%, and 8-10 in 16.02%. 3522 were treated with SBRT alone. 573 patients also received supplemental external beam radiation (median dose 4500cGY) and 1030 patients (25.15%) received Androgen Deprivation Therapy (ADT) as part of their treatment. RESULTS At 75 months the 6-year biochemical relapse free survival was 95.83% in younger patients compared to 98.41% in older patients using the Phoenix definition of biochemical failure. The 6-year median post treatment PSA was 0.3 in younger patients and 0.2 in the older patients. There were no significant differences in the risk stratification between the 2 groups. CONCLUSION This represents the largest series evaluating outcomes in very young patients treated with definitive SBRT for prostate cancer. With updated 6-year follow up, SBRT remains an effective treatment for this younger subset of patients. Continued follow up will be required to see if these results remain durable.
Collapse
Affiliation(s)
- C Mendez
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - J W Lischalk
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - A Katz
- Department of Urology, New York University Langone Hospital - Long Island, Mineola, NY
| | - T J Carpenter
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - M R Witten
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - A Sanchez
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - V Santos
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - A Corcoran
- Department of Urology, New York University Langone Hospital - Long Island, Mineola, NY
| | - E Awad
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - I Trivedi
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - S R Blacksburg
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| | - J Haas
- Department of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Mineola, NY
| |
Collapse
|
4
|
Carpenter TJ. Pregnancy as a cause of chronic pelvic pain. Postgrad Med 1994; 95:31, 132. [PMID: 8170872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
5
|
Abstract
Using a high-sensitivity differential scanning microcalorimeter capable of performing cooling scans, we have examined the phase behavior of small unilamellar vesicles (SUV) as a function of time of storage above their order-disorder phase transition. Vesicles composed of dipalmitoylphosphatidylcholine (DPPC) and dimyristoylphosphatidylcholine (DMPC) were examined. Cooling scans on fresh (5-7-h postsonication) samples revealed broad, relatively simple heat capacity peaks (peak temperatures: 19.9 degrees C for DMPC, 37.8 degrees C for DPPC) free of high-temperature spikes or shoulders. Subsequent heating scans displayed a sharp peak characteristic of previously described fusion products formed below the phase transition. SUV samples stored for 1 or more days above their phase transition displayed a moderately broad, high-temperature shoulder (23.8 degrees C for DMPC and 40.2 degrees C for DPPC) in the cooling profile. For DMPC, the enthalpy associated with this peak increased in a first-order fashion with time. Hydrolysis products were not detected until 12-20 days of storage. Both the rate and extent of shoulder appearance increased with temperature (k = 0.0017 h-1, fraction of total enthalpy = 0.1 at 36 degrees C; k = 0.0037 h-1, fraction = 0.2 at 42 degrees C). Freeze-fracture electron micrographs confirmed that an intermediate-sized vesicle population (diameters 400-500 A) appeared in SUV samples stored above their phase transition. Also, the trapped volume of DMPC SUV increased from 0.26 microL/mumol after 17 h of storage to 0.54 microL/mumol after storage for 16 days at 36 degrees C.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- B R Lentz
- Department of Biochemistry and Nutrition, University of North Carolina, Chapel Hill 27514
| | | | | |
Collapse
|